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ARTICLE
Synthetic energy sensor AMPfret deciphers
adenylate-dependent AMPK activation mechanism
Martin Pelosse1,2,3, Cécile Cottet-Rousselle1, Cécile M. Bidan 4, Aurélie Dupont4, Kapil Gupta3,
Imre Berger 3 & Uwe Schlattner 1
AMP-activated protein kinase AMPK senses and regulates cellular energy state. AMPK
activation by increasing AMP and ADP concentrations involves a conformational switch
within the heterotrimeric complex. This is exploited here for the construction of a synthetic
sensor of cellular energetics and allosteric AMPK activation, AMPfret. Based on engineered
AMPK fused to ﬂuorescent proteins, the sensor allows direct, real-time readout of the AMPK
conformational state by ﬂuorescence resonance energy transfer (FRET). AMPfret faithfully
and dynamically reports the binding of AMP and ADP to AMPK γ-CBS sites, competed by
Mg2+-free ATP. FRET signals correlate with activation of AMPK by allosteric mechanisms
and protection from dephosphorylation, attributed here to speciﬁc CBS sites, but does not
require activation loop phosphorylation. Moreover, AMPfret detects binding of pharmaco-
logical compounds to the AMPK α/β-ADaM site enabling activator screening. Cellular assays
demonstrate that AMPfret is applicable in vivo for spatiotemporal analysis of energy state
and allosteric AMPK activation.
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Maintenance of energy homeostasis in the body is a vitalprerequisite for endergonic cellular processes. Tomaximally exploit the free energy of ATP hydrolysis,
the ratio of ATP to ADP must be kept at a high level. AMP-
activated protein kinase (AMPK) is an evolutionary conserved
heterotrimeric complex capable of sensing and responding to
changes in cellular energy state1–3. AMPK is activated by multiple
parallel and potentially synergistic pathways. However, many of
the underlying molecular mechanisms remain elusive.
In vivo, phosphorylation of T172 in the catalytic α-subunit is
required to activate AMPK, predominantly by liver kinase B1
(LKB1)4,5, but in certain cells types also by calcium/calmodulin-
dependent protein kinase 2 (CaMKK2 or CaMKKβ)6–8, counter-
acted by a range of phosphatases9,10. Importantly, when cellular
ATP is depleted due to imbalanced production and consumption,
AMP and ADP levels increase and competitively replace ATP at up
to two of the four cystathionine beta synthase (CBS) sites, CBS1
and CBS311–13. Pairwise, these CBS sites form two Bateman
domains in the regulatory γ-subunit. CBS4 is likely bound con-
stitutively to AMP in vivo although it can be exchangeable
in vitro14, while CBS2 remains unoccupied9. AMP acts by direct
allosteric activation of AMPK, while both AMP and ADP promote
α-T172 phosphorylation and inhibit dephosphorylation by phos-
phatases13. Most direct pharmacological activators of AMPK,
including A-769662 or compound 991, and likely also a yet to be
identiﬁed intracellular metabolite, bind to the allosteric drug and
metabolite (ADaM) site at the α/β-interface15,16. Allosteric acti-
vation by the ADaM, CBS1, and CBS3 sites appears to be addi-
tive17 and, at least in vitro, sufﬁcient for AMPK activation even in
absence of α-T172 phosphorylation16.
Each of these activation mechanisms requires cross-talk
between the catalytic α and the regulatory β- and/or γ-subunits.
This cross-talk involves a conformational switch which we ﬁrst
observed by small angle X-ray scattering (SAXS) in full-length
AMPK18. Subsequent electron microscopy and X-ray crystal-
lographic studies with truncated heterotrimer conﬁrmed this
switch14,19, revealing an α regulatory subunit-interacting motif
(αRIM) directly contacting CBS3 in the γ subunit19–21. More
recently, solution studies using hydrogen/deuterium exchange
mass spectroscopy (HDX-MS)22,23 or luminescence energy
transfer24 provided insight into CBS site contributions to AMP-
and ADP-induced conformational changes. Again, activator
binding to the ADaM site induces rearrangements between α-
and β-subunits, involving the capping of α-KD by β-CBM24–26.
Once activated, AMPK relieves energy stress by triggering a large
variety of cell-type-speciﬁc responses slowing ATP consumption
while accelerating ATP synthesis, acting on metabolic pathways,
signaling cascades, and gene expression9,11,27. Beyond its central
role in energy homeostasis, AMPK also regulates cell cycle, shape,
motility, proliferation, autophagy, apoptosis, and hypothalamic
appetite control28. Due to these manifold functions, AMPK
became a highly attractive pharmacological target for instance for
treating type II diabetes and obesity29,30.
Here, we set out to harness the adenylate-induced conforma-
tional switch to create a genetically encoded metabolic biosensor
capable of reporting cellular energy states. Our sensor, AMPfret,
relies on FRET occurring between ﬂuorescent proteins (FPs)
fused to suitable AMPK subunit termini as deduced by combi-
natorics. AMPfret faithfully reports on conformational changes
upon binding of allosteric activators, relevant for AMPK activa-
tion and description of cellular energy state. These changes are
readily reversible upon inactivation, in contrast to existing FRET
sensors depending on ﬂuorescent AMPK substrates31–33. We use
our biosensor AMPfret to reveal mechanisms of AMPK activation
in vitro, and to detect allosteric AMPK activation and energy
stress in living cells.
Results
AMPfret design and engineering. AMPfret converts the AMP-
induced conformational change into a measurable signal by
exploiting FRET between two FPs. Based on highly AMP-
responsive α2β2γ1 AMPK34, we ﬁrst fused cyan FP (CFP) and
yellow FP (YFP), respectively, to all combinations of N- or C-
termini of two different AMPK subunits using the ACEMBL
system35 (Table 1, Supplementary Fig. 1a, b). Wild-type AMPK
activity was preserved and measurable FRET was observed in
most constructs (Table 1, Supplementary Figs. 1d, 2). Two fusion
constructs exhibited a FRET change of sufﬁcient magnitude upon
AMP binding to serve as a sensor. These two AMPK variants
shared a CFP-tag at the C-terminus of α2, while the YFP-tag was
either at the C-terminus of γ1 (AMPfret 1.0) or β2 (AMPfret pre-
2.0) (Supplementary Fig. 3a, b). The observed increase in FRET
suggests a more compact conformation of AMP-bound AMPK,
consistent with conformational rearrangements in structural
studies14,18,22,36. In all constructs, FRET values correlated well
with FP distances estimated from published AMPK structures
(PDB IDs: 5ISO and 4CFF)26 (Table 1).
We further engineered AMPfret to maximize adenylate-
induced FRET changes for cellular applications. We removed
presumably ﬂexible low-complexity regions at subunit termini,
and added instead a rigid 8-amino acid α-helix linker between α2
C-terminus and mseCFPΔ11. Meant to amplify molecular
movements of AMPK, this indeed doubled FRET signal change
upon AMP binding (Supplementary Fig. 3c). AMPfret constructs
retained endogenous AMPK afﬁnities for AMP and ADP, as
demonstrated for AMPfret 1.0 (Supplementary Figs. 4, 5).
Importantly, AMPfret 2.0 also responded to compound 991, an
activator targeting the ADaM site (Suppl. Figure 3c). To further
optimize the sensor, we selected the more efﬁcient mseCFPΔ11/
cpVenus FRET pair37 resulting in AMPfret 1.1 and AMPfret
2.1 sensors (Fig. 1, Table 1).
Adenylate-dependent rearrangements and allosteric activation.
Our AMPfret biosensors faithfully report changes in AMP con-
centration occurring already below 10 µM and faster than the 10 s
temporal resolution (Fig. 1d)38. The concentration dependence of
this sensitive and rapid response by ﬂuorometry conﬁrmed
saturation below 15 µM and yielded an afﬁnity constant below
2 µM (Fig. 2a, Supplementary Fig. 4b, e), corroborating that
AMPfret senses physiologically relevant AMP concentrations.
Next, we tested ADP, which is likewise an indicator of cellular
energy depletion and a known AMPK activator. In a physiological
concentration range, FRET measurements yielded an afﬁnity
constant of 7.5 µM for ADP (Supplementary Fig. 4c, f). FRET
changes induced by AMP were stable over a wide range of pH
and salt conditions (Supplementary Fig. 4g, h) and not detected if
GMP was used (Fig. 2b). AMP-induced FRET changes also cor-
related well with AMP-dependent allosteric activation of AMP-
fret, as determined with CaMKKβ-pre-activated sensor and
acetyl-CoA carboxylase (ACC) as kinase substrate (Fig. 2a, red
trace). A slight shift of AMPfret activity towards higher AMP
concentrations in the kinase assay is likely due to the presence of
ATP (competing with AMP) and higher temperature (affecting
CBS binding constants; Supplementary Fig. 4i). We conclude that
AMPfret retains wild-type afﬁnity for adenylates and responds to
their ﬂuctuations within a physiological range. Moreover, our
sensor also reports allosteric activation of phosphorylated
AMPfret by AMP.
T172 phosphorylation and AMP-dependent rearrangements.
We investigated the impact of AMPK activation loop phos-
phorylation on AMP-dependent FRET signal change (Fig. 2c).
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The critical activation loop residue T172 was either phosphory-
lated by CaMKKβ, or replaced with a phospho-mimetic (T172D)
or non-phosphorylatable mutation (T172A). None of these
alterations caused any effect on the AMP-induced FRET
response. Even in a physiological setup of 3 mM MgATP com-
peting with AMP, both T172D and T172A mutants reacted
similarly to AMP. Thus, AMP binding to the γ-subunit and the
resulting conformational changes are independent of phosphor-
ylation of the activation loop.
AMPfret enables AMPK activator screening. We asked whether
AMPfret can report allosteric activation by small molecule AMPK
activators A-769662 (20 µM) or compound 991 (2 µM) occurring
at the ADaM site. AMPfret 1.1 and even more so AMPfret 2.1
exhibited pronounced FRET increase with 991, while the response
to A-769662 was insigniﬁcant (Fig. 2d). These results are con-
sistent with the ADaM site involving the β-subunit (tagged in
AMPfret 2.1), and 991 exhibiting high afﬁnity to the β2 subunit
(present in all AMPfret sensors). In contrast, A-769662 pre-
ferentially binds β1-AMPK27. Re-screening of our initial con-
structs for their response to 991 conﬁrmed that those most
responsive to AMP are also most responsive to 991 (Supple-
mentary Table 1), suggesting that both allosteric activators trigger
similar activating AMPK conformations. We further investigated
the effect of A-769662 in presence or absence of AMP to account
for potential cumulative effects (Fig. 2e). In the presence of 20 µM
AMP, A-769662 increased the FRET ratio in a concentration-
dependent manner, supporting an additive effect of A-769662
and AMP for AMPK activation, consistent with previous
reports39,40. Indirect AMPK activators inhibiting mitochondrial
respiration, such as metformin41,42 did not trigger a FRET
change. Also, local conformational changes induced in the α-
subunit kinase domain by the kinase inhibitor staurosporine did
not translate into an activating conformation of the entire het-
erotrimeric complex as detected by AMPfret (Fig. 2d). Nicoti-
namide adenine dinucleotides (NADs) were reported to bind to
CBS sites20 and directly activate AMPK in case of NADH43,
although this has been subject to debate44. With AMPfret, even
NADs concentrations exceeding physiological45,46 failed to trig-
ger FRET signal change, taking into account contaminating AMP
in the NAD preparation (Supplementary Fig. 6). We thus
postulate that NADs do neither induce any activating AMPK
conformation in cells in vivo. In summary, AMPfret biosensor
can be used for screening AMPK activators interacting at the γ-
CBS sites and also at the α/β ADaM site.
Functional role of CBS sites. AMPfret allows direct monitoring
of conformational changes that have been linked to allosteric
activation by AMP and protection from dephosphorylation by
ADP and AMP, in absence of ATP normally required for kinase
assays. This enabled us to directly analyze the individual roles of
AMP and ADP for the three adenylate-binding CBS sites by site-
speciﬁc mutations (CBS1: L128D+V129D, CBS3: V275G+L276G,
CBS4: S315P)14 that preserved kinase activity (Supplementary
Figs. 1e, 5a–d). Our experiments clearly conﬁrmed CBS3 as the
main site of conformational response to saturating concentrations
of both AMP and ADP (Fig. 3a)14,47. Mutation of CBS1 only
diminished the FRET response to AMP but did not affect the ADP
response. Surprisingly, an inverse situation was observed when
mutating CBS4, which abolished the FRET response triggered by
ADP, but not by AMP.
We subjected all CBS mutants to relevant AMPK activity
assays using immunodetection of P-ACC and P-AMPK or to 32P
incorporation into ACC (Fig. 3b–d, Supplementary Fig. 5e–h).
Allosteric activation by increasing amounts of AMP was about
twofold in unmutated AMPfret and CBS4 mutant, but much
reduced in CBS1 mutant, and entirely lacking in CBS3 mutant. In
fact, activation of CBS1 mutant was biphasic, without activation
below 5 µM AMP, and reduced activation at higher concentra-
tions. These data are in excellent agreement with observed AMP-
induced FRET changes. Protection from dephosphorylation of
T172-phosphorylated AMPfret in presence of PP2Cα and
increasing amounts of AMP or ADP was observed in unmutated
AMPfret and again absent in CBS3 mutant. In contrast to what
we observed with allosteric activation, CBS1 mutant showed here
characteristics of unmutated sensor. Interestingly, CBS4 mutation
did not affect protection by AMP, but only blunted protection by
ADP - again in excellent agreement with the FRET data. Our
results thus indicate that CBS3 is essential for conformational
changes that lead to allosteric activation and protection from
dephosphorylation. CBS1 appears to be necessary for full
allosteric activation, but is dispensable for protection from
Table 1 Overview of AMPfret constructs tested for AMP responses
AMPfret construct Organization YFP peaka FRET ratiob Distances (Å)c FRET changed
AMPK 221 α2 _ β2 _ γ1 / / / /
AMPfret A (AMPfret pre-2.0) α2-CFP _ β2-YFP _ γ1 ++ 1.444 13.8 +
AMPfret B CFP-α2 _ β2-YFP _ γ1 ± 0.492 78.9 −
AMPfret C (AMPfret 1.0) α2-CFP _ β2 _ γ1-YFP + 0.639 59.8 +
AMPfret D α2-CFP _ β2 _ YFP-γ1 ± 0.513 62.7 −
AMPfret E CFP-α2 _ β2 _ γ1-YFP − / 78.5 −
AMPfret F (AMPfret CTL) CFP-α2 _ β2 _ YFP-γ1 − / 72.7 −
AMPfret G α2 _ β2-YFP _ γ1-CFP ± 0.524 50.0 −
AMPfret H α2 _ YFP-β2 _ γ1-CFP ± 0.464 (63.3) −
AMPfret I α2 _ β2-YFP _ CFP-γ1 + 0.637 53.1 −
AMPfret J α2 _ YFP-β2 _ CFP-γ1 ± 0.559 (58.2) −
AMPfret K α2-CFP _ YFP-β2 _ γ1 + 0.648 (67.8) ±
AMPfret L CFP-α2 _ YFP-β2 _ γ1 − / (17.7) −
AMPfret 2.0 α2-helix-CFP _ β2-YFP _ γ1 ++ 2.032 19.0 ± 11.6 ++
AMPfret 1.1 α2-mseCFPΔ11 _ β2 _ γ1-cpVenus + 0.727 55.0 +
AMPfret 2.1 α2-helix-mseCFPΔ11 _ β2-cpVenus _ γ1 ++ 2.026 19.0 ± 11.6 ++
aYFP peak visibility annotated as: ++ strong, + detectable, ± shoulder, – absent
bFRET ratio (YFP/CFP) at baseline
cDistances between tagged termini determined from PDB IDs: 5ISO and 4CFF26. In brackets: distances involving the β N-ter lacking in these structures. For AMPfret 2.0/2.1: a range is given, since
orientation of the added α-helix linker could not be predicted
dChange of FRET ratio upon AMP addition annotated as: ++ strong, + average, ± detectable, – non-detectable
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Fig. 1 FRET changes in response to AMP. a AMP-dependent variation of ﬂuorescence emission spectra of AMPfret constructs 1.1 and 2.1 and AMPfret-
negative control (CTL) (blue line: no AMP, orange line: 20 µM AMP). Spectra normalized to the isosbestic point at 512 nm. AMPfret topologies are
depicted on top (bars: AMPK subunits, red box: putatively rigid helix, blue circles: cyan ﬂuorescent protein mseCFPΔ11, yellow circles: yellow ﬂuorescent
protein cp173-mVenus). b Normalized FRET ratio of AMPfret constructs calculated from a (same color code), and corresponding autoradiograms of in vitro
kinase activity assays using acetyl-CoA carboxylase (ACC) as substrate. Data and error bars represent mean ± SEM (n≥ 7, *p < 0.001, Student’s t-test).
c Schematic drawing of AMPfret 2.1 operating mode. Within an α2β2γ1 AMPK heterotrimer (α: blue, β: orange, γ: pink), a CFP variant (blue circle) fused to
a small rigid α-helix linker (red) was added at the α2-C-terminus, while a YFP variant (yellow circle) was added at the β2-C-terminus. Binding of AMP (and
ADP) to the γ-subunit induces a conformational change which modiﬁes distance and/or orientation between the ﬂuorophore couple, thus increasing the
non-radiative energy transfer (FRET; black wave) between them. Excitation/emission wavelengths are indicated. The model is based on AMPK core
structures co-crystalized with either ATP (PDB ID: 4EAK) or AMP (PDB ID: 4EAI)16 and extended for missing parts by the full-length AMPK structure (PDB
ID: 5ISO), thus visualizing some of the conformational changes (AMPK in schematic backbone representation, ATP and AMP in space ﬁlling
representation). d Kinetics experiments of AMPfret 1.1 (left) and AMPfret control (CTL, right) responses to the addition of 10 µM AMP: the ratiometric
FRET signals were measured every 10 s, corrected for cross-talk (CT= 0.20) and direct excitation (DE= 0.04) and normalized by the average signal
before addition of AMP. Gray and black lines represent individual samples and their mean, respectively (n= 5)
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dephosphorylation. Of note, our experiments show that CBS4,
previously described as a non-exchangeable site26, is apparently
not involved in AMP-triggered allosteric activation or protection
mechanisms but may be required for ADP-mediated protection.
AMPK regulation by free ATP and adenylate mixtures. How
AMPK can sense low micromolar concentration of AMP in
presence of a millimolar concentration of ATP, a difference of
three orders of magnitude, remains a profound riddle. It was
proposed that only non-complexed (free) ATP but not MgATP
competes with AMP48–50. Indeed, different afﬁnities for ATP as
compared with MgATP were determined for CBS sites23. AMP-
fret enabled us, to directly test this hypothesis, since AMPfret
readout does not require ATP (Fig. 4a). The baseline FRET signal
and the FRET increase induced by 20 µM AMP or 200 µM ADP
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Fig. 2 FRET changes report AMPK allosteric activation. a AMP-concentration dependence of FRET (black) compared to AMP-induced allosteric activation
(red) of AMPfret 1.0. This activation was determined with pre-activated AMPK in presence of 200 µM ATP, followed by immunoblotting for
phosphorylated acetyl-CoA carboxylase (ACC; insert); quantiﬁed band intensities were normalized to control at 0 µM AMP. Data and error bars represent
mean ± SEM (n≥ 3). Note: ATP in the kinase assay shifts the curve to higher AMP concentrations. b GMP-concentration dependence of FRET, showing
absence of FRET change. Points represent mean ± SEM (n≥ 3). c Phosphorylation of T172 does not interfere with AMP-induced conformational changes
reported by FRET. AMPfret 1.0 wild type (WT), pre-phosphorylated (P-T172), or mutated (T172A/D) proteins were incubated in absence (blue) or in
presence of 20 µM AMP (orange), or with additional 3 mM Mg2+-complexed ATP (orange dashed red). Note: FRET changes are independent of MgATP.
Data and error bars represent mean ± SEM (n≥ 3). d AMPfret response to different AMPK activators. AMPfret 1.1 (left) or 2.1 (right) were incubated
in absence (blue) or in presence of AMP (20 µM, orange), A-769662 (20 µM, green), 991 (2 µM, green), metformin (500 µM, white) or staurosporine
(25 µM, purple). Note: no FRET change is induced by the indirect activator metformin or the protein kinase inhibitor staurosporine. Data and error bars
represent mean ± SEM (n≥ 4). e Additive effect of allosteric activators bound to CBS (AMP) and ADaM sites (A-769662). FRET ratio of AMPfret 2.0
incubated with A-769662 (5–20 µM) in absence (green) or presence of 20 µM AMP (green dashed orange). Note: a concentration-dependent effect of A-
769662 is only signiﬁcant in presence of AMP. Data and error bars represent mean ± SEM (n≥ 3). All FRET signals are normalized to control (no
adenylates). After checking normality and equality of variance, statistical signiﬁcance was analysed by two-way ANOVA followed by Bonferroni multiple
comparison. Means sharing the same letter do not differ signiﬁcantly (p≤ 0.02)
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increasing concentrations of AMP and ﬁxed MgATP (200 µM) by immunoblotting for phosphorylated acetyl-CoA carboxylase (P-ACC; see Supplementary
Fig. 5) and data normalized to kinase activity in absence of AMP. Data and error bars represent mean ± SEM (n= 3). c, d AMP- and ADP-dependent
protection against dephosphorylation of AMPfret WT and its CBS site mutants. AMPK activity was quantiﬁed with pre-phosphorylated AMPK,
phosphatase PP2Cα and increasing concentrations of AMP or ADP by immunoblotting for α-subunit P-T172 (see Supplementary Fig. 5) and data
normalized to dephosphorylation in absence of ADP. Data and error bars represent mean ± SEM (n= 3). After checking normality and equality of variance,
statistical signiﬁcance was analysed by two-way ANOVA followed by Student–Newman–Keuls multiple comparison. Means sharing the same letter do not
differ signiﬁcantly (p≤ 0.02)
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were not sensitive to excess Mg2+ in our experiments, in agree-
ment with structural studies performed with AMP in the presence
or absence of Mg2+ ions51. Complementation of 20 µM AMP
with 3 mM ATP entirely reversed the FRET signal to baseline,
clearly showing competition of free ATP with AMP for inducing
conformational changes. However, when excess Mg2+ was added,
the resulting MgATP had no detectable effect, indicating that
MgATP did not compete with AMP. These results compellingly
demonstrate that only free ATP but not MgATP competes with
AMP for binding to CBS sites causing conformational changes,
rationalizing the mechanism of AMPK sensing ﬂuctuations in
ATP, ADP, and AMP levels despite their vastly different cellular
concentrations.
Using most sensitive AMPfret 2.1, we analyzed in more detail
how physiological mixtures of adenylates affect AMPK con-
formational changes (Fig. 4b). In presence of 3 mM Mg2+,
addition of 20 µM AMP or 200 µM ADP increased the FRET
signal, while 3 mM ATP (yielding 0.5 mM free ATP) did not, as
expected. Adding AMP and ADP in combination led to a
maximal FRET increase of about 20%. Further addition of ATP
into this incubation mixture clearly reduced the FRET signal.
Next, approximating physiological conditions, we choose a
baseline resting state of 1 µM AMP, 100 µM ADP and 4 mM
ATP (Fig. 4b), i.e. lower AMP and ADP concentrations as used
earlier for unstressed conditions23. This mixture did not alter the
baseline FRET signal, thus demonstrating that free ATP (1.2 mM
in this case) could entirely outcompete AMP and ADP at the CBS
binding sites under these conditions. To simulate cellular energy
stress, where ATP consumption exceeds ATP generation and the
adenylate kinase reaction adjusts new adenylate equilibria, we
increased AMP (20-fold) and ADP (ﬁvefold), and decreased ATP
(by 0.9-fold), thus decreasing free ATP (by 0.75-fold). Under such
conditions, the FRET signal increased by about 7%. Since free
ATP seems to be a decisive parameter for AMPK activation, but
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baseline FRET (blue bars) and FRET induced by AMP (orange) or ADP (yellow), but prevents ATP-induced FRET inhibition (red). Plain and dashed bars,
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its true physiological value is difﬁcult to estimate, we further
varied ATP concentrations while keeping AMP and ADP
concentrations constant. With a decrease of free ATP to about
0.5 mM, the FRET ratio further increased to about 10% above
resting state. Our data lead to important conclusions. First, also in
physiological adenylate mixtures, the monitored conformational
changes rely on a binding equilibrium between free ATP and
AMP or ADP at the AMPK CBS sites, leading to dynamic
regulation of AMPK activation. Moreover, energy stress-related
adenylate mixtures trigger FRET changes up to about 10%, a
value to be expected when deploying AMPfret 2.1 into living cells,
and which should allow relative quantiﬁcation of adenylates or
adenylate ratios.
AMPfret sensor in living cells. To deploy AMPfret 2.1 in living
cells, we pasted AMPfret genes into our MultiMam system52 for
mammalian cell transfection. HEK293t, 3T3-L1, and HeLa were
transiently transfected with AMPfret 2.1 to observe FP signal
(Fig. 5). AMPfret was detected mainly in the cytoplasm of these
cell lines (Fig. 5a, e, h), providing proof-of-concept evidence for
the spatial resolution of AMPfret signals and suggesting that
compartment-speciﬁc detection is feasible using our sensor.
Nuclear AMPfret ﬂuorescence was present, but not sufﬁcient to
reliably calculate FRET (Supplementary Fig. 7). We speculate that
a putative nuclear localization signal in α2 may be obstructed by
the FP in the tagged construct, while a nuclear export signal
identiﬁed in the α-C-terminal part remains active53. Next, we
supplied cells with 1 mM AICAR to allosterically activate AMPK,
and recorded AMPfret emission spectra over time (Fig. 5b). In all
three cell lines tested, half-maximal response occurred during the
ﬁrst 5–6 min, reaching saturation at about 30 min (Fig. 5c, f, i).
With an AMPfret response to AMP occurring faster than 10 s
(Fig. 1d), this kinetics probably reﬂects cellular AICAR uptake
and conversion into the AMP-analogue ZMP. Maximal FRET
signals (4–5% for HEK293T and HeLa, ~7% for 3T3-L1) and
their variability differed slightly among the cell types. This may
reﬂect cell-type-speciﬁc differences, or different AMP/ATP ratios
at basal conditions to which the curve was normalized. If the
latter was the case, then higher AMP/ATP ratios at baseline
would diminish the exploitable FRET signal range for subsequent
experiments. Under the same conditions, we separately deter-
mined AMPK activation in 3T3-L1 cells by detection of phos-
phorylated ACC (Fig. 5g). The excellent correlation between
FRET signal and AMPK activation kinetics in 3T3-L1 under-
scores that AMPfret can indeed report allosteric AMPK activation
in living cells. To further explore whether AMPfret can be used
for detection of both allosteric AMPK activation and spatio-
temporal analysis of endogenous adenylate ratios, we inhibited
glycolysis in HEK293t cells (Fig. 5c) by using 2-deoxyglucose (2-
DG, 3.3 g/L) at low glucose (1 g/L) as compared to normal glucose
(4.5 g/L). Again, AMPfret responded by an increase in the FRET
signal, but much slower as compared to AICAR, with a half-
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Fig. 5 AMPfret in cellulo. a–d HEK293T cells transfected with AMPfret 2.1. a Micrograph of CFP and YFP channels (scale bars: 50 µm). b Fluorescence
emission spectra before (0 min, blue) and after addition (30min, red) of 1 mM AICAR, showing increase at 527 nm (cpVenus) and decrease at 478 nm
(mseCFPΔ11) over 30min. c Normalized AMPfret FRET signal variation (YFP ﬂuorescence at 530 ± 5 nm/CFP ﬂuorescence at 478 ± 5 nm) after incubation
with 1 mM AICAR (black), 20mM 2-DG (red) or complete medium (control CTL, blue). Data of cell population normalized to values before treatment.
Data and error bars represent mean ± SEM (n= 64, n= 27, and n= 39 cells from at least two independent experiments for 2-DG, AICAR, and control,
respectively). d HPLC quantiﬁcation of adenylates in HEK293T cells treated for 50min with complete medium (control CTL, blue) or 20mM 2-DG medium
(red). Curve (average of three-independent experiments) showing peaks with typical retention times of 5.5 min (ATP), 6.5 min (ADP) and 10.8 min (AMP),
and adenylate ratios calculated thereof (same color code). e–g 3T3-L1 cells transfected with AMPfret 2.1. e Micrograph of CFP and YFP channels (scale
bars: 50 µm). f Normalized AMPfret FRET signal variation after incubation with 1 mM AICAR. Data of cell population normalized to values before AICAR
addition. Data and error bars represent mean ± SEM (n= 9 cells of two-independent experiments). g AICAR-dependent activation of AMPK veriﬁed by
parallel immunoblots for P-ACC and ACC (lower panel) and their quantiﬁcation (upper panel). Data and error bars represent mean ± SEM (n= 3). After
checking normality and equality of variance, statistical signiﬁcance was analysed by one-way ANOVA followed by Bonferroni multiple comparison. Means
sharing the same letter do not differ signiﬁcantly (p≤ 0.02). h, i HeLa cells transfected with AMPfret 2.1. h Micrograph of CFP and YFP channels (scale
bars: 50 µm). i Normalized AMPfret FRET signal variation after incubation with 1 mM AICAR. Data of cell population normalized to values before AICAR
addition. Data and error bars represent mean ± SEM (n= 51 cells of three-independent experiments)
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maximal response occurring only after ~25 min At the end of the
45 min observation period, the FRET signal was already about
twice as high as with AICAR, without yet reaching saturation.
These data are consistent with ongoing energy depletion induced
by 2-DG, slowly decreasing ATP and increasing ADP and AMP
levels, which then translate into allosteric AMPK activation.
Direct quantiﬁcation of adenylates by HPLC conﬁrmed that the
AMPfret signal 50 min after 2-DG addition corresponds to a 2-
and 10-fold increase of ADP/ATP and AMP/ATP ratios,
respectively (Fig. 5d). Different to 2-DG, AICAR uptake directly
generates the allosteric activators ZMP and AMP, but does not
alter ADP and ATP levels, probably causing the more rapid
activation, but liming the maximal AMPfret signal. These data
provide compelling evidence that AMPfret indeed affords readout
of endogenous adenylate ratios. Of note, AMPfret readout pri-
marily depends on adenylate concentrations and their ﬂuctuation,
independent of AMPK T172 phosphorylation. Since phosphor-
ylation is required for full kinase activation, AMPfret reports
allosteric activation in cells only if basal T172 phosphorylation is
afforded by active AMPK kinases.
Discussion
Freely accessible pools of cytosolic ATP, ADP and AMP con-
stitute the major source of free energy driving metabolism, and
they represent the most fundamental readout to describe changes
in cellular energy state54. Biochemical or NMR-based measure-
ments in whole cells and tissues or extracts have limits, since they
do not account for both compartmentalized and structurally
bound adenylates, or fail to detect small alterations. In principle,
genetically encoded ﬂuorescent reporters55 can be engineered to
provide information on physiologically relevant, local adenylate
concentrations31,37,56. Here we exploit the naturally evolved
adenylate afﬁnities of the key metabolic regulator AMPK57 to
create our genetically encoded synthetic sensor, AMPfret. Using a
matrix approach for positioning FRET reporter pairs, we identi-
ﬁed and optimized two distinct AMPfret constructs exhibiting
exploitable AMP-dependent FRET changes. AMPfret faithfully
reports conformational changes within the full-length, fully
functional AMPK heterotrimer linked to altered AMP/ATP and
ADP/ATP ratios sensed at the CBS sites, and the resulting AMPK
activation in vitro and in living cells. AMPfret is also sensitive to
pharmacological activators such as compound 991 binding at the
ADaM site. Thus, AMPfret allows mechanistic studies of AMPK
activation, monitoring cellular energy state, and identiﬁcation of
AMPK activators. It further provides direct evidence for the
conformational switch model of AMPK activation that we pro-
posed earlier based on SAXS with wild-type AMPK hetero-
trimer18, later conﬁrmed by structural and biochemical
studies14,21,36,58 which used truncated AMPK subunits14, or
indirect in vitro isotope or chemical tagging approaches22–24.
AMPfret constructs that produced suitable FRET signal
changes are tagged exclusively at the C-termini of either α2 and
γ1 (AMPfret 1.0/1.1) or α2 and β2 (AMPfret 2.0/2.1), which
imply that these termini are moving signiﬁcantly relative to each
other upon AMP or ADP binding. HDX-MS analysis also
revealed singular changes close to the C-termini of β2 and γ1,
while in α2 changes appeared to occur mostly within the active
site22,23. None of our β2/γ1-tagged constructs show signiﬁcant
AMP-induced FRET variation, suggesting that these subunits do
not move signiﬁcantly relative to each other. This does not
exclude structural rearrangements in the core of the β- and γ-
subunits24 or a movement of both tagged termini as a rigid body
relative to the α-C-terminus. Likewise, no AMP-induced FRET
variation is seen with the N-terminally tagged α2/γ1-pair,
although distance variations were reported between α1/γ1-N-
termini24. Likely, movements between α/γ- C-termini are much
more important.
AMPfret retains wild-type AMPK properties, including kinase
activity, regulation by phosphorylation, and native adenylate
afﬁnities that evolved to sense critical adenylate changes at the
onset of cellular energy stress44. Nuclear import of AMPfret is
reduced, but still occurring. The FRET readout directly correlates
with sensor-bound adenylates, thus AMPfret reports physiologi-
cally relevant increase in AMP/ATP and ADP/ATP ratios. This
provides a useful tool to detect, with good temporal resolution,
cellular energy states, and AMP- or ADP-dependent AMPK
activation, i.e. allosteric activation and protection of depho-
sphorylation. FRET changes occur independent of AMPK αT172
phosphorylation, with both γ-CBS and α/β-ADaM site activators,
and thus already report an increased potential for AMPK acti-
vation in absence of upstream kinases. This may be an advantage
in cellular models that lack sufﬁcient upstream kinase activity.
However, although canonical AMPK activation requires αT172
phosphorylation, there is increasing evidence for an allostery-only
activation by the sole additive or synergistic action of CBS and
ADaM site activators16,40,59. Although the achieved activity may
remain lower in cells as compared to in vitro assays60, this opens
new avenues for AMPK activating treatments, and AMPfret is
able to report such activation. All these properties unique to our
AMPfret tool set it apart from known AMPK activity reporters
based on artiﬁcial, ﬂuorescent AMPK substrates31,33. Those do
not report the contribution of altered cellular energy state and are
limited in their temporal resolution for detecting AMPK activa-
tion, and in particular inactivation (which would depend on
separate phosphatase activities). An important advantage of
AMPfret for in vitro studies is its activation-related FRET. In
contrast to classical kinase activity assays, it does not require
ATP, which is prone to non-enzymatic degradation to ADP and
AMP44,61, all interfering with binding at the CBS sites. Thus,
AMPfret represents a powerful tool to analyze adenylates with
respect to the different activation mechanisms, as we demon-
strated here. AMPfret reports binding of AMP (in absence of
ATP) at one or more binding sites in a range up to 20 μM and
with an afﬁnity of about 1.5 μM, close to expected values20,34,44.
The two exchangeable CBS sites20 either have similar afﬁnity for
AMP, or the difference cannot be resolved by ﬁtting the AMPfret
concentration-response curve. Similar to AMP, ADP induces a
FRET signal indicating a single afﬁnity (in absence of ATP) in the
range of about 7.5 µM. For both adenylates, competition with free
ATP in vivo would shift the binding curve to higher AMP con-
centrations as seen in the kinase activity assays, in very good
agreement with physiological ﬂuctuations of these adeny-
lates20,62,63. Thus, AMPfret afﬁnities likely describe the true
responsiveness of AMPK to AMP and ADP, in contrast to some
published afﬁnities appearing either too high (in the sub-
micromolar range)24 or too low23. AMPfret also enabled us to
closely analyse the inﬂuence of non-complexed (free) as com-
pared to Mg2+-complexed ATP. Our data compellingly demon-
strate that not only for CBS binding23,34, but also for induced
conformational changes the true competitor of AMP (and ADP)
is non-complexed ATP, which is at least 10-times less abundant
in cells as compared to MgATP, while there is no effect of Mg2+
on AMP and ADP. This rationalizes how micromolar AMP
concentrations can outcompete 1000-times higher total ATP
concentrations for AMPK activation20,64. Importantly, neither of
the two forms of ATP induced a FRET signal on their own,
challenging the notion that ATP can serve as an active allosteric
modulator24. However, the fact that we do not see ATP-induced
movements in our AMPfret sensors characterized here does not
rule out the possibility that ATP-induced conformational changes
may exist, requiring further future study.
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Mutating the different adenylate-binding CBS sites within
AMPfret led to key insight into allosteric regulation by adenylates
at the mechanistic level of induced conformational changes. CBS3
appears to be essential for conformational alterations by both
AMP and ADP, involving allosteric activation (by AMP) and
protection from dephosphorylation (by AMP and ADP). This is
in agreement with mutational14,23 and structural ﬁndings25,26
which showed that CBS3 harboring several naturally occurring
mutants involved in cardiac pathologies (e.g. R531G/Q)65,66 can
transmit conformational changes to the catalytic α-subunit
involving a presumably unstructured loop region comprising
the α-RIM1 and α-RIM2 motifs interacting with CBS2 and CBS3,
respectively19,21. Mutation at CBS1 reduces AMP-dependent
conformational changes and attenuates AMP allosteric activation,
in particular by shifting it to higher concentrations. This suggests
that AMP-binding to CBS1 is required for full allosteric activa-
tion, consistent with earlier models19,24. ADP-dependent con-
formational changes were unaltered by CBS1 mutation,
suggesting that this site is not involved in protection from
dephosphorylation. CBS4 can exchange nucleotides under
extreme conditions, and is typically occupied by AMP or ADP
also in recombinantly produced complex14. Occupation of this
site was reported to increase AMP binding at CBS323, but CBS4
mutation in AMPfret did not show any signiﬁcant effect on FRET
and allosteric activation. In contrast, we found that mutating S315
at CBS4 fully abolished ADP-induced changes. Since we see this
effect speciﬁcally only with ADP and not with AMP, an indirect
effect of S315P on CBS3 afﬁnities is unlikely.
Consistent with the notion that the active state of AMPK
adopts a unique, compact conformation with many conserved
features20,21,25,26, AMPfret reports movements of the same sub-
unit termini with similar amplitude for AMP and ADP. However,
they also unveil hitherto unknown differences in AMP- and
ADP-dependent conformational changes, since each involves a
speciﬁc set of CBS sites. Indeed, since ADP acts through pro-
tection of the α subunit from dephosphorylation13 and not via
allosteric activation, induced conformational changes must differ
at the molecular level from those induced by AMP. These dif-
ferences may be linked to the manner α-RIM1 and α-RIM2
motifs connect the kinase domain with the CBS sites19,21.
In vivo, ADP and AMP signals would occur together, with
ATP consumption immediately increasing ADP, and - via the
adenylate kinase reaction - also AMP9,67. Indeed, our data are
consistent with both adenylates being important for AMPK
activation in vivo, with activating conformational changes
occurring at physiologically relevant concentrations, in particular
very low micromolar AMP, and by using physiological adenylate
mixtures. Although AMPfret was not designed for monitoring
binding of direct AMPK activators to the ADaM site at the α/β
interface25,26,68, AMPfret 2.1 (α2/β2-pair FP-tagged) revealed
increased FRET when incubated with 991, in contrast to A-
769662, consistent with the lower afﬁnity of the β2 isoform for
this activator15,69. The conformational changes reported by
AMPfret here are likely different to those triggered by AMP or
ADP binding to CBS sites, but apparently result in a similar
reduction in the distance between α2/β2-C-termini. This fact,
together with the almost identical outcome of our construct
screening with AMP and 991, may reﬂect overall similar intra-
molecular and intermolecular rearrangements within the AMPK
heterotrimer, irrespective of the initial activator or binding site
involved, as also suggested earlier23. These are different from
conformational changes triggered by binding at the kinase
domain active site, as staurosporine does not induce an AMPfret
signal.
CBS and ADaM sites can cooperate in allosteric activation to a
degree that activates AMPK even when not phosphorylated at α-
T172 in vitro16,40,59. Such synergy between activated CBS and
ADaM sites induces an overall conformation close to α-T172-
phosphorylated AMPK60 which we could determine in vitro by
observing similar responses of AMPfret 2.1 to AMP and com-
pound 991. Although with currently available synthetic activators
such allostery-only activation seems to be limited in human
cells60, there is signiﬁcant potential here for future pharmacolo-
gical development. Indeed, AMPK modulators are much sought
after to treat metabolic diseases70. With its design and conserved
native features of AMPK activation, AMPfret is a powerful tool to
screen and identify direct activators binding to γ-CBS and α/β-
ADaM sites. AMPfret does not report binding of antagonistic
competitors like ATP, kinase substrates or inhibitors, or indirect
activators like metformin. This could be advantageous for iden-
tifying the elusive endogenous metabolite binding at the ADaM
site, which may provide allosteric AMPK activation independent
of energy state or even T172 phosphorylation27,59. Further,
AMPfret can likely be engineered to distinguish between ADaM
site activators with preference for β1 or β2 subunits.
AMPfret 2.1 reports AICAR- and 2-DG-induced FRET signals
in different cell lines minutes after addition, very likely directly
following AICAR conversion into the AMP-analogue ZMP or
inhibition of glycolysis, respectively. The different time course
and magnitude of the AMPfret response to AICAR and 2-DG
illustrate how AMPfret reports changes in endogenous adenylate
ratios and thus cellular energy state. As shown here in 3T3-L1
cells, AMPfret monitors adenylate levels and allosteric AMPK
activation without apparent lag phase. This sets AMPfret apart
from existing AMPK activity reporters based on artiﬁcial ﬂuor-
escent substrates that require about an hour to detect AICAR
effects31. Since the AMPfret signal is directly proportional to the
activation-linked conformational change, it should also rapidly
reverse upon decreasing AMP or ADP levels, as it does in vitro
when adding ATP. This would allow the analysis of transient
AMPK activation, difﬁcult to achieve with available AMPK sub-
strate reporters with reversibility depending on phosphatases.
Finally, since AMPfret reports conformational changes in absence
of T172 phosphorylation, it can even be used in cell lines lacking
signiﬁcant upstream kinase activity, like HeLa cells33.
An advantage of genetically encoded protein-based biosensors
is that, in principle, any parameter can be ﬁne-tuned by molecular
engineering. During the present work, we have successfully
improved FRET amplitudes by introducing more advanced FPs
and by increasing the signal range by ~100% with the insertion of
a small, rigid α-helix. The resulting 20% range in the AMPfret 2.1
FRET signal in vitro may still be limiting for certain applications
in living cells. It is conceivable that further optimization of
AMPfret to improve the FRET range by engineering could pro-
vide an even more powerful sensor. Since AMPfret is a reporter of
AMPK allosteric activation that occurs under conditions of
metabolic stress and that can be engaged by synthetic ligands,
experiments can be envisioned to identify potent AMPK mod-
ulators. Importantly, the ﬂexible design of our AMPfret con-
structs facilitates switching subunit isoforms to screen for
isoform-speciﬁc activators that could have tissue-speciﬁc
effects71, and screening of endogenous metabolites that allos-
terically activate at the ADaM site. We anticipate many exciting
roles for AMPfret in a wide range of applications, as a highly
versatile tool to accelerate discovery.
Methods
Molecular cloning. AMPK subunits used in this work are the AMPK α2 catalytic
subunit from Rattus norvegicus (PRKAA2; Gene ID: 78975), the AMPK β2 subunit
from Homo sapiens (PRKAB2; Gene ID: 5565) and the γ1-subunit isoform from
Rattus norvegicus (PRKAG1; Gene ID: 25520). All AMPfret constructs carry an N-
terminal deca-histidine tag and a protease cleavage site for tobacco etch virus
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(TEV) NIa protease on the sequence coding for α2. In the ﬁrst generation of
AMPfret biosensors (including AMPfret 1.0 and 2.0), ECFP and EYFP were fused
to tag the aforementioned AMPK subunits by sequence and ligation-independent
cloning method (SLIC)72 or conventional restriction cloning (see Supplementary
Table 2 for primer list). Through a matrix approach, made possible by the ver-
satility of the MultiColi expression system35, all combinations of full-length AMPK
heterotrimer tagged on two of its three subunits with either a CFP variant or a YFP
variant at the N- or C-terminus were created. α2-, β2-, and γ1-derived AMPfret
subunits were, respectively, cloned in pACE1, pDC and pDS of the MultiColi
expression system. For the most recent AMPfret generation (AMPfret 1.1 and 2.1)
we used the mseCFPΔ11/cp173Venus FRET pair. Mutations at the α2T172 (T172D
and T172A) and at three γ1 CBS sites shown to abrogate adenylate binding16,23
(CBS1: L128D + V129D, CBS3: V275G + L276G and CBS4: S315P), truncations
and linker engineering at the interface of AMPK subunit and the FP were realized
by Self-SLIC73. Brieﬂy, it consisted in amplifying the whole backbone of a coding
vector using primers that contain the desired mutation plus an overlapping region,
which allowed the self-recircularization after T4 DNA polymerase exonuclease
treatment. False-positive products are avoided by a digest of the PCR template
using Dpn1. Identiﬁcation of mutated clones was facilitated by the introduction of
new restriction sites without changing the amino acid sequence, taking advantage
of the redundancy of the genetic code. Expression vectors were obtained through
Cre-LoxP recombination of the single subunit containing plasmids. For in cellulo
work, AMPfret 2.1 subunits were transferred by SLIC into plasmids of the Mul-
tiMam expression system (α2-mseCFPΔ11, β2 and γ1-cp173Venus, respectively, in
pACEMam2, pMDS and pMDK)52. Positive clones were identiﬁed through
extensive restriction digest pattern analysis and all constructs were veriﬁed by DNA
sequencing.
Protein engineering. Two strategies were applied to amplify the AMP-induced
FRET ratio of AMPfret. First, we removed non-folded residues located at the
termini of AMPK subunits and ﬂuorescent proteins. Residues were identiﬁed
through the examination of X-ray structure available at that time (PDB IDs: 2Y94
and 5ISO20) and secondary structure prediction. Second, based on observations by
Sivaramakrishnan et al. that ER/K amino acids repeat forms a rigid α-helix74, we
positioned such motifs (2- to 12-AA length) between the α-subunit and CFP. Only
one α-helix linker was inserted to ﬁx one ﬂuorophore, thus avoiding to increase
distance between both of them.
Expression and puriﬁcation. All versions of AMPfret were expressed in BL21
(DE3) Star cells (Invitrogen) and protein expression was carried out overnight at
18 °C in autoinducing medium75. Cells were collected by centrifugation and ﬂash
frozen in liquid nitrogen. For puriﬁcation, bacterial cell pellets were resuspended in
Lysis buffer (0.5 M sucrose, 30% glycerol, 50 mM Tris, pH 8, 100 mM NaCl, 2 mM
MgCl2, 2 mM β-mercaptoethanol, 20 mM imidazole and protease inhibitors). Next,
bacterial cells were lysed by sonication and cell-free extract obtained by cen-
trifugation (60 min, 75,000 g, JLA 25.50 rotor) was applied on Ni-NTA Superﬂow
resin (Qiagen). Resin was then washed with lysis buffer, wash buffer (50 mM Tris,
pH 8, 100 mM NaCl, 20 mM imidazole, 2 mM MgCl2, 2 mM β-mercaptoethanol)
and high salt buffer (wash buffer + 1 M NaCl). Proteins were eluted by applying
elution buffer (wash buffer + 400 mM imidazole). Imidazole was removed through
an overnight dialysis in buffer A (50 mM Tris, pH 8, 100 mM NaCl, 2 mM MgCl2,
2 mM β-mercaptoethanol). AMPfret protein complexes were applied onto a QXL
column (GE Healthcare) to remove nucleic acids and non-stochiometric AMPK
complexes. AMPfret complexes were eluted using a 100 mL continuous gradient of
buffer B (50 mM Tris, pH 8, 1 M NaCl, 2 mM MgCl2, 2 mM β-mercaptoethanol)
and were collected at a salt concentration of ~200 mM NaCl. For maximal pur-
iﬁcation, AMPfret constructs were applied onto a Superose 6 10/300 gel ﬁltration
column (GE Healthcare) preequilibrated with SEC buffer (50 mM Tris, pH 8, 200
mM NaCl, 2 mM MgCl2, 2 mM β-mercaptoethanol, 5 mM spermidine). AMPfret
eluted at a volume corresponding to globular proteins of a ~280 kDa molecular
weight, suggesting a rather elongated shape of AMPfret. After adding glycerol to a
ﬁnal concentration of 50%, the puriﬁed AMPfret constructs were placed at −20 °C
until use for further experiments. Purity was assessed at each puriﬁcation step
through SDS-PAGE analysis.
Enzymatic kinase assay. AMPfret constructs and AMPK 221WT (3 pmol) were
activated by incubation with puriﬁed CaMKKβ (1 pmol) for 20 min at 30 °C in
kinase buffer (200 µM ATP, 40 µM AMP, 5 mM MgCl2, 1 mM DTT, and 10 mM
HEPES pH 7.4). Puriﬁed GST-ACC fragment (200 pmol) was incubated for 20 min
at 37 °C in presence of pre-activated AMPfret constructs in kinase buffer con-
taining 200 µM [γ−32P]-ATP (speciﬁc activity 650 mCi/mmol ATP). Reaction
mixtures were then separated on SDS-PAGE gel. Speciﬁc AMPfret activities were
revealed using a Typhoon imaging system (GE Healthcare). AMP-dependent
allosteric activation was evaluated under the same conditions, except that various
concentrations of AMP were used. Enzymatic kinetics of AMPfret constructs
and their CBS site mutants were performed as above in presence or absence of
AMP (20 µM) in the kinase buffer, except that less AMPfret sensor was used
(200 fmol). To stop the reaction at given time points, protein loading dye was
added to the reaction mixture and immediately heated to 98 °C for 3 min AMPK
kinase activity was also revealed by immunoblotting for P-Ser79-ACC and total
ACC (see immunoblots) using unlabeled ATP. ADP-dependent protection against
dephosphorylation was assessed using AMPfret constructs pre-phosphorylated by
CaMKKβ and repuriﬁed over a Superose 6 10/300 column. Then, AMPfret (50 ng)
was incubated with PP2Cα (200 ng; Sigma) for 2 h at 37 °C in presence of various
amounts of ADP (0–200 µM). The phosphorylation status of AMPfret constructs
was evaluated by immunoblotting for P-T172 α-subunit and total α-subunit (see
immunoblots). The amount of PP2Cα to use and other conditions were determined
through preliminary tests.
Fluorometric FRET assay. FRET signal variation in presence of different com-
pounds (nucleotides, chemicals, ions) was measured using a ﬂuorometer (Photon
Technology International). Excitation wavelength was set to 430 nm, and emission
spectra were recorded from 450 to 600 nm with a step size of 1 nm and an
integration time of 0.2 s. AMPfret constructs (15 pmol) were incubated in a quartz
cuvette (Hellma) in a ﬁnal volume of 150 µL (Spectro buffer: 50 mM Tris, pH 8,
200 mM NaCl, 5 mM MgCl2, 2 mM β-mercaptoethanol). Effects of nucleotides and
other compounds (prepared in Spectro buffer) were assessed by comparing FRET
ratios (ratio of emission maxima at 527 ± 2 nm and at 476 ± 2 nm) in their pre-
sence or absence. Mg2+ effects on FRET were investigated with variable con-
centrations of Mg2+ (0–10 mM) and AMPfret stock solution diluted to yield ﬁnal
Mg2+ concentrations below 20 µM. Once acquired using the Felix software, spectra
were treated under Excel or SigmaPlot 13.0. In concentration series, data were
ﬁtted with Sigma Plot 13.0 to single site binding kinetics. Ratios between Mg2+ and
free ATP and the derived amount of Mg2+-ATP were calculated using Maxchelator
software at http://maxchelator.stanford.edu at the given experimental conditions.
Ratiometric FRET kinetics. To estimate the kinetics of the response of the
AMPfret biosensors at 10 s resolution, we used an epiﬂuorescence microscope
(Olympus IX83). The changes in ratiometric FRET signal were monitored in a
volume of 200 µL of AMPfret 1.1 or negative control AMPfret CTL (both 20
pmoles) in Spectro buffer. AMP concentration was successively increased by
addition of 1 µL of 2 mM AMP stock solution every 10 min, i.e. 10 µM steps. Every
10 s, the solution was alternatively excited with 442 nm and 515 nm light (Fianium
supercontinuum laser) and both CFP (donor) and YFP (acceptor) signals were
simultaneously acquired on a sCMOS camera (Hamamatsu ORCA-Flash 4.0 v2).
Practically the two emission channels (donor and acceptor) were split with a
dichroic mirror (510LP, F48–510, AHF Technologies), ﬁltered (519LP F37–519
and 475/50 F39–477, AHF Technologies, Chroma) and spatially shifted to ﬁt
simultaneously on the camera chip. This alternating-laser excitation method
(ALEX)38 enabled us to obtain the FRET ratio corrected for cross-talk (CT) and
direct excitation (DE) from the formula,
FRET ratio ¼ IDA  CT:IDD  DE:IAA
IDD
; ð1Þ
where IDA is the average intensity collected in the acceptor channel upon donor
excitation (442 nm), IDD is the average intensity collected in the donor channel
upon donor excitation, IAA is the average intensity collected in the acceptor channel
upon acceptor excitation (515 nm). The theoretical values of the correction factors
CT= 0.20 and DE= 0.04 were calculated from the speciﬁcations of the ﬁlters used
and the ﬂuorophore spectra. We normalized the FRET ratios for each experiment
to the average basal value calculated over the 10 min before the ﬁrst addition of
AMP in the solution, and ﬁnally averaged the ﬁve experiments. The calculation was
done using Matlab software (MathWorks).
Cell culture and transfection and treatments. 3T3-L1 (ATCC, CL-173) and
HeLa cells (ATCC, a gift from Prof. Peter Cullen, Univ. of Bristol, UK) were
cultured in Dulbecco Modiﬁed Eagle Medium (DMEM, Institut de Biotechnologies
Jacques Boy) containing 4.5 g/L glucose, 10% SVF (Pan-Biotech, lot P291905),
10 mM HEPES (PAA cell culture company), penicillin and streptomycin (Gibco) as
well as non-essential amino acids (Sigma). HEK293T cells (ATCC, CRL-3216) were
cultured in DMEM (Gibco 41965039) containing 4.5 g/L glucose, 10% SVF,
penicillin and streptomycin. For transfection of cells at ~80% conﬂuence, medium
was replaced by OptiMEM (Gibco) and MultiMam-derived AMPfret 2.1 coding
plasmid was transfected using either Lipofectamine 2000 (Invitrogen) for 5–6 h
(3T3-L1 and HeLa cells) or PolyFect transfection reagent (Qiagen) following
manufacturer recommendations (HEK293T cells). For extracts, cells were grown to
~80% conﬂuence in Ø35 mm dishes before replacing the medium by either fresh
complete medium (control), complete medium with AICAR (1 mM ﬁnal), or 2-DG
medium (containing 3.3 g/L 2-DG, 1 g/L glucose instead of 4.5 g/L glucose), and
cells grown for variable time until lysis. For AMPfret analysis, cells cultured in 8-
well Labtek (Nunc) in complete medium was observed by the confocal microscopy.
Medium was then replaced by complete medium containing AICAR (1 mM ﬁnal)
or 2-DG (3.3 g/L 2-DG and 1 g/L glucose) without moving the 8-well plates.
Confocal microscopy. AMPfret transfected cells were observed with a Leica TCS SP2
or SP8, both equipped with an incubation chamber (37 °C, 5% CO2) and a Plan Apo
×63/1.40 oil or a HCX plan Apo ×20/0.70 dry as objectives. The instrument’s
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autofocus system was used (LCS SP8) or z-stacks (4 tiles distributed through 10 µm)
were acquired and combined (LCS SP2) to avoid focal drift during the experiments
and to tolerate cell shape remodeling. For excitation, the 458 nm Argon laser (<20%
power) was used and pictures were taken at 512 × 512 or 1024 × 1024 pixel resolution
with a 400 Hz scanning frequency and 4 lines averaging in the CFP (478 ± 5 nm) and
the YFP (530 ± 5 nm) channels every 5min for 40–60min using HyD (LCS SP8) or
PMT (LSC SP2) detectors. After averaging of z-stacks intensities and background
subtraction (rolling ball radius: 200 pixels) using FIJI, both CFP and YFP ﬂuorescence
intensity values were extracted from the recorded pictures using FIJI. FRET signal
variations for single cells were calculated from averaged ﬂuorescence intensities (YFP
ﬂuorescence value/CFP ﬂuorescence value).
Protein-free extracts and HPLC nucleotide analysis. HEK293T cells were put on
ice and washed three times with PBS before lysis and metabolic quenching with
0.6N perchloric acid for 1 min Lysate and cell debris were then scraped, centrifuged
(2 min, 13,000 rpm, 4 °C), supernatants neutralized with 2 N KOH, 0.3 M MOPS
and again centrifuged (10 min, 13,000 rpm, 4 °C). In these supernatants and in
solutions of commercial ATP, NADH, and NADPH (Roche), adenylates were
quantiﬁed by HPLC (Varian with Proplus autosampler 410; Agilent Polaris
C18 stationary phase; 60% CH3CN, 40% H2O mobile phase; detection at 254 nm)
using calibration curves established for each nucleotide.
Protein extracts and immunoblots. 3T3-L1 cells were ﬂash-frozen in liquid
nitrogen and put on ice. 200 µL of buffer containing 50 mM Tris, pH 8, 200 mM
NaCl, 2 mM β-mercaptoethanol were added and cells were scratched and then
frozen in liquid nitrogen. After thawing, cells were sonicated 5 s. Lysates were
clariﬁed by centrifugation and supernatant was kept. Proteins were quantiﬁed using
the Bradford reagent and identical protein amounts were loaded onto 7.5% SDS-
PAGE gels. Proteins transferred on a nitrocellulose membrane were probed with
antibodies (all rabbit, dilution 1:1000, Cell Signaling) against total ACC (#3662), P-
Ser79-ACC (#3661), total AMPKα (#2532), or P172-AMPKα (#2535). Speciﬁc
bands were visualized using a LAS 4000 imager (GE Healthcare) and P-ACC and
ACC bands were quantiﬁed using ImageJ.
Statistics. Data are presented as mean ± standard error of the mean (SEM) and
statistically analyzed by Sigma Plot 11.0 (Systat Software Inc., San José, CA, USA).
Data were checked for normality (Shapiro–Wilk) and equal variance. If not stated
otherwise, data were then analyzed for signiﬁcance by one-way or two-way
ANOVA, depending on the experimental design, followed by post hoc multiple
pairwise comparison by either Bonferroni or Student–Newman–Keuls methods.
Differences were considered signiﬁcant when p ≤ 0.02. In the ﬁgures, means
sharing the same letter do not differ signiﬁcantly.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Data supporting the ﬁndings of this manuscript are available from the corresponding
authors upon reasonable request. A reporting summary for this Article is available as a
Supplementary Information ﬁle. The source data underlying Figs. 1b, 2a, 5g and
Supplementary Figs. 1b-e, 3b, 6e-h are provided as a Source Data ﬁle.
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